Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2017

01-09-2017 | Original Article – Clinical Oncology

Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma

Authors: Sangjun Yoo, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2017

Login to get access

Abstract

Purpose

We compared the oncological outcomes of papillary renal cell carcinoma (pRCC) with clear cell renal cell carcinoma (ccRCC) after partial nephrectomy (PN) in patients with pathologic T1a RCC.

Methods

After excluding patients with synchronous multiple renal tumors, familial RCC, and pathologic stage T1b or above, 759 patients with ccRCC and 84 patients with pRCC were included. We assessed the impact of histologic subtypes on oncologic outcomes after PN in patients with pathologic T1a RCC (median follow-up duration, 67 months).

Results

There was no difference in patient and tumor characteristics between the 2 groups, except Fuhrman grade (p = 0.006). Kaplan–Meier analysis identified 5-year recurrence-free survival of 98.7 and 95.6% in patients with ccRCC and pRCC, respectively. However, 10-year recurrence-free survival in patients with ccRCC and pRCC was 96.1 and 73.0%, respectively (p < 0.001). Recurrence ≥5 years post surgery was more common in patients with pRCC compared with those with ccRCC (0.3 vs. 4.8%; p < 0.001). In multivariate analysis, pRCC [hazard ratio (HR) 5.309; p = 0.001] was a significant risk factor for recurrence after PN in patients with pathologic T1a RCC, in addition to larger tumor size (HR 1.861; p = 0.038) and Fuhrman grade ≥3 (HR 5.176; p = 0.003).

Conclusions

In patients with pathologic T1a RCC, recurrence after PN occurred more commonly in pRCC compared with ccRCC. As over half of the recurrence cases in patients with pRCC occurred ≥5 years post surgery, a longer follow-up time is required, even for those with pathologic stage T1a disease.
Literature
go back to reference Ha YS et al (2016) Clinical significance of subclassification of papillary renal cell carcinoma: comparison of clinicopathologic parameters and oncologic outcomes between papillary histologic subtypes 1 and 2 using the Korean renal cell carcinoma database. Clin Genitourin Cancer 45(2):e181–e186. doi:10.1016/j.clgc.2016.07.020 CrossRefPubMed Ha YS et al (2016) Clinical significance of subclassification of papillary renal cell carcinoma: comparison of clinicopathologic parameters and oncologic outcomes between papillary histologic subtypes 1 and 2 using the Korean renal cell carcinoma database. Clin Genitourin Cancer 45(2):e181–e186. doi:10.​1016/​j.​clgc.​2016.​07.​020 CrossRefPubMed
go back to reference Kuthi L et al (2016) Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res POR. doi:10.1007/s12253-016-0179-x PubMed Kuthi L et al (2016) Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res POR. doi:10.​1007/​s12253-016-0179-x PubMed
go back to reference Levey AS et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRefPubMed Levey AS et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRefPubMed
go back to reference Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML (2008) Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 179:468–471. doi:10.1016/j.juro.2007.09.077 (discussion 472–463) CrossRefPubMed Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML (2008) Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 179:468–471. doi:10.​1016/​j.​juro.​2007.​09.​077 (discussion 472–463) CrossRefPubMed
go back to reference Yamamoto A, Tamada T, Ito K, Sone T, Kanki A, Tanimoto D, Noda Y (2017) Differentiation of subtypes of renal cell carcinoma: dynamic contrast-enhanced magnetic resonance imaging versus diffusion-weighted magnetic resonance imaging. Clin Imaging 41:53–58. doi:10.1016/j.clinimag.2016.10.001 CrossRef Yamamoto A, Tamada T, Ito K, Sone T, Kanki A, Tanimoto D, Noda Y (2017) Differentiation of subtypes of renal cell carcinoma: dynamic contrast-enhanced magnetic resonance imaging versus diffusion-weighted magnetic resonance imaging. Clin Imaging 41:53–58. doi:10.​1016/​j.​clinimag.​2016.​10.​001 CrossRef
go back to reference Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS (2017) Performance of relative enhancement on multiphasic MRI for the differentiation of clear cell renal cell carcinoma (RCC) from papillary and chromophobe RCC subtypes and oncocytoma. AJR Am J Roentgenol 208(4):812–819. doi:10.2214/ajr.16.17152 CrossRefPubMed Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS (2017) Performance of relative enhancement on multiphasic MRI for the differentiation of clear cell renal cell carcinoma (RCC) from papillary and chromophobe RCC subtypes and oncocytoma. AJR Am J Roentgenol 208(4):812–819. doi:10.​2214/​ajr.​16.​17152 CrossRefPubMed
Metadata
Title
Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma
Authors
Sangjun Yoo
Dalsan You
In Gab Jeong
Cheryn Song
Bumsik Hong
Jun Hyuk Hong
Hanjong Ahn
Choung-Soo Kim
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2430-6

Other articles of this Issue 9/2017

Journal of Cancer Research and Clinical Oncology 9/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.